Skip to main navigation

About Us
Focus
Pipeline & Products
Technology
- Overview
- PRINT
Patients
Medical Professionals
Investors
Careers

Publications

Pioneers in rare cardiopulmonary disease

Explore the science behind our clinical trials.

Search

Categories

June 9, 2022

| Poster

Kingman, M and Patel, S.

Quality of Life (QoL) in PAH Patients Receiving an Inhaled Dry Powder Treprostinil (LIQ861) in the INSPIRE Study. PHA International Conference

Atlanta, GA

May 16, 2022

| Poster

Hill N. S., et al.

Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH): Results from INSPIRE Study. ATS Annual Meeting

San Francisco, CA

May 15, 2022

| Presentation

Hill N. S., et al.

Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH): Results from INSPIRE Study at 1 Year. ATS Annual Meeting

San Francisco, CA

April 27, 2022

| Poster

Sahay, Sandeep

Risk Assessment in Pulmonary Arterial Hypertension (PAH): Insights From the INSPIRE Study With LIQ861. 42nd Annual Meeting of International Society for Heart and Lung Transplant (ISHLT)

Boston, MA

February 2, 2021

| Article

Roscigno RF, Vaughn T, Parsley E, Hunt T, Eldon MA, Rubin LJ

Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects

August 5, 2020

| Poster

Hill N. S., et al.

INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861in Pulmonary Arterial Hypertension (PAH) – Exploratory Efficacy Endpoints Analysis at Month 2. American Thoracic Society Annual Meeting – Virtual

April 30, 2020

| Presentation

Hill N. S., et al.

INSPIRE: Final Results from a Phase 3, Open-Label, Pivotal Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension. ISHLT Annual Meeting

April 26, 2020

| Poster

Maynor B., et al

Nonclinical, In-silico, and Clinical Evaluation of LIQ861 Inhalation Powder Deposition and Pharmacokinetics Digital Respiratory Drug Delivery 2020

April 26, 2020

| Full Abstract

Maynor B., et al

Nonclinical, In-silico, and Clinical Evaluation of LIQ861 Inhalation Powder Deposition and Pharmacokinetics Digital Respiratory Drug Delivery 2020; 2020 Apr 26

March 20, 2020

| Article

Roscigno R.,et al.

Roscigno R.,et al. Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil. Pulmonary Circulation 2020; 10(4) 1–9; DOI: 10.1177/2045894020971509

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Page 5
…
Next page
Last page

Socials

Science

Company

Investors

Copyright © 2026 Liquidia Corporation. All Rights Reserved.

Accessibility
Cookie Policy
Legal
Privacy Policy